|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0205042,
umls-concept:C0205210,
umls-concept:C0221198,
umls-concept:C0302891,
umls-concept:C0541315,
umls-concept:C0687568,
umls-concept:C1261322,
umls-concept:C1515568,
umls-concept:C1516634,
umls-concept:C1522577,
umls-concept:C1705899
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-2-4
|
|
pubmed:abstractText |
This paper reports the 3-year clinical outcomes of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) compared with the TAXUS (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stent (PES) in the randomized SPIRIT II (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions) study.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1876-7605
|
|
pubmed:author |
pubmed-author:BolandJeanJ,
pubmed-author:DorangeCécileC,
pubmed-author:GarciaEulogioE,
pubmed-author:GargScotS,
pubmed-author:HuberKurtK,
pubmed-author:Miquel-HébertKarineK,
pubmed-author:OnumaYoshinobuY,
pubmed-author:SPIRIT II Investigators,
pubmed-author:SerruysPatrickP,
pubmed-author:SudhirKrishnankuttyK,
pubmed-author:VeldhofSusanS,
pubmed-author:te RieleJan A MJA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1190-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20129545-Aged,
pubmed-meshheading:20129545-Angioplasty, Balloon, Coronary,
pubmed-meshheading:20129545-Cardiovascular Agents,
pubmed-meshheading:20129545-Coronary Angiography,
pubmed-meshheading:20129545-Coronary Artery Disease,
pubmed-meshheading:20129545-Coronary Restenosis,
pubmed-meshheading:20129545-Drug-Eluting Stents,
pubmed-meshheading:20129545-Europe,
pubmed-meshheading:20129545-Female,
pubmed-meshheading:20129545-Humans,
pubmed-meshheading:20129545-Kaplan-Meier Estimate,
pubmed-meshheading:20129545-Male,
pubmed-meshheading:20129545-Middle Aged,
pubmed-meshheading:20129545-Myocardial Infarction,
pubmed-meshheading:20129545-Paclitaxel,
pubmed-meshheading:20129545-Prospective Studies,
pubmed-meshheading:20129545-Prosthesis Design,
pubmed-meshheading:20129545-Risk Assessment,
pubmed-meshheading:20129545-Risk Factors,
pubmed-meshheading:20129545-Single-Blind Method,
pubmed-meshheading:20129545-Sirolimus,
pubmed-meshheading:20129545-Thrombosis,
pubmed-meshheading:20129545-Time Factors,
pubmed-meshheading:20129545-Treatment Outcome,
pubmed-meshheading:20129545-United States
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
|
|
pubmed:affiliation |
Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
